GHP Funds

SVP I

SVP I, the debut fund for the firm, closed in December 2002 and invested with four highly successful leveraged buyout funds. SVP I is diversified by sector and geography.

Learn More
SVP II

SVP II is a leveraged buyout fund of funds which closed in December 2006. SVP II represents a continuation of the successful strategy utilized by the predecessor fund, primarily investing with large, top tier LBO and growth equity firms. SVP II is diversified by sector and geography.

Learn More
SVP RE I

SVP Real Estate I, LP ("SVP RE I"), closed in February 2008, is a private real estate fund of funds. As with SVP I & II, SVP RE I received allocations with historically successful, highly sought after underlying fund managers who pursue compelling investment strategies. The fund is diversified by sector (Office, Hotel, Industrial/Warehouse, Retail and Residential) and geography (U.S., Europe, and Asia/Pacific).

Learn More
GHP COF

The GHP Credit Opportunity Fund (“GHP COF”) is a fund of alternative credit and distressed debt funds that is being raised and invested to pursue two specific investment themes: (1) the de-leveraging of European Banks, and (2) the potential for a distressed cycle in U.S. High Yield Credit. GHP COF will pursue complex liquid and illiquid credit opportunities in the U.S. and Europe.

Learn More

GHP Library

HelloMD Expands International Reach with South African Joint Venture

SAN FRANCISCO, March 27, 2019 /PRNewswire/ — HelloMD — the country’s leading digital healthcare platform for cannabis doctors, consumers and brands — is expanding to international markets in the process of legalizing medical cannabis. Today the company announced a joint venture has been created with Tetracann to serve the South African (and other African) markets.

HelloMD was founded in 2014 in San Francisco, and has grown into one of the world’s largest online wellness-oriented cannabis communities and the nation’s first and only digital healthcare platform to provide HIPPA-compliant video chats between cannabis doctors and patients in every state. The company also operates in Canada. HelloMD’s patient education, onboarding and product sales platform will soon be localized for the emerging African market along with hundreds of proprietary articles, medical Q&As, videos, and other patient educational materials critical for large-scale onboarding of new medical cannabis consumers.

We chose the African market for this expansion because we have identified strong local business partners there, who will be capitalizing and operating a cross-section of HelloMD-branded services.

Mark Hadfield, CEO of HelloMD

Having successfully on-boarded over one hundred thousand new consumers in the US, we can apply that experience, technology, process and content to emerging markets, bringing local cannabis patients rapidly up-to-speed as successful medical cannabis consumers in emerging markets.

A version of HelloMD’s website will be localized for the South African market launch, planned for the end of Q2, 2019. In addition to the educational content for patients, telehealth-based doctor consults along with tools to help facilitate local clinic services will be made available. The platform’s e-commerce capabilities will also be deployed for CBD and THC product sales in select areas. All services will be branded as HelloMD.

Recently, Prohibition Partners estimated that the size of the African cannabis market could be upwards of $7 billion by 2023.

“We are committed to providing medical cannabis consumers in South Africa and beyond, with quality medical advice, information and leading products,” stated Matthew Moodley, CEO of Tetricann. “We believe that HelloMD represents best of breed technology and educational material. Our JV and the localization of their platform will provide South African, doctors and patients with immediate access to quality medical information which will enhance a wellness orientated cannabis community in Southern Africa.”

Moodley also added, “As South Africa joins the rapidly expanding number of countries that have recognized the medicinal value of cannabis through its regulation, the HelloMD platform will assist in meeting the significant demand both for information about the plant and its benefits as well as access to class-leading products.”

HelloMD has made its mark in the U.S. and Canadian markets by growing the largest community of medical cannabis consumers. In a short period of time, over 100,000 patient and doctor consultations have been conducted, and an engaged community of over 250,000 is growing month to month. The company plans to be operating in multiple international territories within the year.

About HelloMD:

HelloMD is the country’s leading digital healthcare platform for cannabis doctors, consumers and brands, and has facilitated more than 100,000 virtual consults between cannabis patients and licensed practitioners. HelloMD’s patient education, onboarding and product sales features can be quickly localized to meet regulatory and patient requirements in markets across the world. Through joint-ventures or white-label solutions, HelloMD partners leverage its platform to attract, nurture, convert and retain patient demand for medical cannabis.

For more information about HelloMD, visit www.hellomd.com or connect with us at: partners@hellomd.com

About Tetracann

Tetracann is a South African company that forms part of a vertically integrated group of companies under the Africann brand. Africann holds licenses to produce medicinal cannabis in Lesotho, Zimbabwe and Democratic Republic of Congo. It has formed strategic alliances for extraction technology and expertise and separately, for product supply, with a number of North American corporations that are leaders in their respective fields. Africann has built distribution channel to supply cannabis based pharmaceuticals and nutraceuticals (both CBD and THC) into the South African medical, pharmaceutical, pet and health and wellness markets. Africann has also commenced building supply relationships into the UK and Cyprus. It is Africann’s strategic objective to produce medicinal cannabis products for both the local market- at affordable price points- as well as for Europe’s burgeoning medicinal cannabis market.

Original Press Release

Leave a Comment